ATE217799T1 - Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten - Google Patents

Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten

Info

Publication number
ATE217799T1
ATE217799T1 AT99906067T AT99906067T ATE217799T1 AT E217799 T1 ATE217799 T1 AT E217799T1 AT 99906067 T AT99906067 T AT 99906067T AT 99906067 T AT99906067 T AT 99906067T AT E217799 T1 ATE217799 T1 AT E217799T1
Authority
AT
Austria
Prior art keywords
porphyria
enzyme
treatment
pbgd
analogue
Prior art date
Application number
AT99906067T
Other languages
English (en)
Inventor
Jens Fogh
Paer Gellerfors
Original Assignee
Hemebiotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemebiotech As filed Critical Hemebiotech As
Application granted granted Critical
Publication of ATE217799T1 publication Critical patent/ATE217799T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT99906067T 1998-01-27 1999-01-27 Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten ATE217799T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK11298 1998-01-27
DKPA199801748 1998-12-30
PCT/DK1999/000040 WO1999037325A2 (en) 1998-01-27 1999-01-27 Method for treating acute intermittent porphyria (aip) and other porphyric diseases

Publications (1)

Publication Number Publication Date
ATE217799T1 true ATE217799T1 (de) 2002-06-15

Family

ID=26063333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99906067T ATE217799T1 (de) 1998-01-27 1999-01-27 Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten

Country Status (11)

Country Link
EP (1) EP1049487B1 (de)
JP (1) JP2002501032A (de)
AT (1) ATE217799T1 (de)
AU (1) AU750143B2 (de)
CA (1) CA2319096C (de)
DE (1) DE69901536T2 (de)
DK (1) DK1049487T3 (de)
ES (1) ES2177240T3 (de)
NO (1) NO327241B1 (de)
PT (1) PT1049487E (de)
WO (1) WO1999037325A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
EP1202744B1 (de) * 1999-07-27 2006-01-04 Zymenex A/S Herstellung von rhpbgd
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
HUE042402T2 (hu) 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére
CN102227500B (zh) 2008-09-29 2013-05-29 阿姆斯特丹分子治疗(Amt)有限公司 胆色素原脱氨酶基因治疗
EP2729566B1 (de) 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Verfahren zur reinigung von arylsulfatase a
WO2013119880A1 (en) 2012-02-07 2013-08-15 Global Bio Therapeutics Usa, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
CA2896979C (en) 2013-01-09 2023-05-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
CN105813579B (zh) 2013-08-08 2019-05-07 全球生物疗法有限公司 用于微创手术过程的夹具装置和其应用
EP3458104A1 (de) * 2016-05-18 2019-03-27 Modernatx, Inc. Polynukleotide zur codierung von porphobilinogendeaminase zur behandlung von akuter intermittierender porphyrie
US11390854B2 (en) 2017-05-09 2022-07-19 Fundacion Para La Investigacion Medica Aplicada Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2657345B2 (ja) * 1992-04-17 1997-09-24 新日本製鐵株式会社 医療用診断装置および疾患判断方法

Also Published As

Publication number Publication date
EP1049487A2 (de) 2000-11-08
DK1049487T3 (da) 2002-09-16
CA2319096A1 (en) 1999-07-29
EP1049487B1 (de) 2002-05-22
CA2319096C (en) 2007-07-03
WO1999037325A2 (en) 1999-07-29
PT1049487E (pt) 2002-10-31
DE69901536T2 (de) 2003-01-16
ES2177240T3 (es) 2002-12-01
JP2002501032A (ja) 2002-01-15
AU2609799A (en) 1999-08-09
WO1999037325A3 (en) 1999-09-30
DE69901536D1 (de) 2002-06-27
AU750143B2 (en) 2002-07-11
NO20003830D0 (no) 2000-07-26
NO327241B1 (no) 2009-05-18
NO20003830L (no) 2000-09-27

Similar Documents

Publication Publication Date Title
DE69901536T2 (de) Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
Sueyoshi et al. A new function of kininogens as thiol-proteinase inhibitors: inhibition of papain and cathepsins B, H and L by bovine, rat and human plasma kininogens
Seiler et al. Polyamines and the intestinal tract
BR0307871A (pt) Proteìnas contendo domìnio de folistatina
DE69823852D1 (de) Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
Schallreuter et al. In VivoEvidence for Compromised Phenylalanine Metabolism in Vitiligo
RU2010150428A (ru) Композиции для усиления антибактериальной активности миелопероксидазы и способы их применения
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
EA200501413A1 (ru) Местные композиции, содержащие l-карнитин
BR112019020367A2 (pt) modulação da expressão do gene para sirtuína com decapeptídeo-12 em progenitores de queratinócito epidérmico
Kusakabe et al. Occurrence of a novel enzyme, L-lysine oxidase with antitumor activity in culture extract of Trichoderma viride
ATE337712T1 (de) Zusammensetzung zur intestinalen verabreichung
Simkin Protein biosynthesis
Meléndez-Hevia et al. Glycine can prevent and fight virus invasiveness by reinforcing the extracellular matrix
Damink et al. Upper gastrointestinal bleeding: an ammoniagenic and catabolic event due to the total absence of isoleucine in the haemoglobin molecule
ATE315084T1 (de) Herstellung von rhpbgd
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
CN103747793A (zh) 含有大豆蛋白质的水解物的组合物
Abe et al. Some properties of a cysteine proteinase inhibitor from corn endosperm
Borsook Enzymatic syntheses of peptide bonds
Śliwa-Jóźwik et al. Influence of exogenous glutathione (GSH), as stressfactor, on the activity of lysosome enzymes in some organs of mice
BR9913377A (pt) Composto derivado de aminoálcool
DE69413637T2 (de) Verwendung von verzweigtkettigen Aminosäuren zur Herstellung eines Arzneimittels zur Behandlung von tardiver Dyskinesia
Moore et al. Inactivation of gamma-glutamylcysteine synthetase, but not of glutamine synthetase, by S-sulfocysteine and S-sulfohomocysteine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1049487

Country of ref document: EP

EEIH Change in the person of patent owner